Valeant sweetens offer for Allergan again

Published



Valeant Pharmaceuticals International has sweetened its offer to buy Botox maker Allergan for the second time this week.

The Canadian drugmaker said Friday it will now offer $72 and a portion of its stock for each Allergan share. That’s up from an offer of $58.30 and a portion of stock per share that Valeant extended on Wednesday.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.